This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Guangdong Longfu Medicine Co., Ltd.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Jinxiang Deng: Innovator in Pharmaceutical Chemistry
Introduction
Jinxiang Deng is a notable inventor based in Zhongshan, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. His work focuses on addressing critical health issues through innovative solutions.
Latest Patents
Deng holds a patent for "Butylphthalide-telmisartan hybrids, preparation method and application thereof." This invention discloses a butylphthalide-telmisartan heterocomplex, along with its preparation method and applications. Specifically, it relates to an optically active ring-opening butylphthalide-telmisartan heterocomplex, or a pharmaceutically acceptable salt or ester thereof. The invention is particularly relevant for the prevention and treatment of neuroinflammation-related diseases, including ischemic stroke, Alzheimer's disease, brain trauma, Parkinson's disease, multiple sclerosis, and depression. He has 1 patent to his name.
Career Highlights
Deng is currently associated with Guangdong Longfu Medicine Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the pharmaceutical industry, contributing to the creation of effective therapeutic agents.
Collaborations
Throughout his career, Jinxiang Deng has collaborated with notable colleagues, including Tao Pang and Zhangjian Huang. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Jinxiang Deng's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in addressing complex health challenges. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in various neuroinflammatory conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile